Carna Biosciences Management
Management criteria checks 2/4
Carna Biosciences' CEO is Kohichiro Yoshino, appointed in Apr 2003, has a tenure of 21.67 years. directly owns 1.75% of the company’s shares, worth ¥98.50M. The average tenure of the management team and the board of directors is 12.8 years and 6.8 years respectively.
Key information
Kohichiro Yoshino
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 21.7yrs |
| CEO ownership | 1.7% |
| Management average tenure | 12.8yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Aug 06
What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You
Apr 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Apr 11How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?
Feb 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Dec 26
CEO
Kohichiro Yoshino (75 yo)
21.7yrs
Tenure
Dr. Kohichiro Yoshino, Ph. D. is Independent Outside Director of Kringle Pharma, Inc since December 2018. Dr. Yoshino serves as the Chief Executive Officer of Carna Biosciences, Inc. He has been President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Representative Director | 21.7yrs | no data | 1.75% ¥ 98.5m | |
| GM of Business Mgt. | 9.3yrs | no data | 0.29% ¥ 16.1m | |
| GM of Research & Development Division | no data | no data | 0.56% ¥ 31.3m | |
| Head of Drug Discovery & Support Business | 16.4yrs | no data | 0.53% ¥ 30.1m | |
| GM of Clinical Development | 5.8yrs | no data | 0.086% ¥ 4.9m |
12.8yrs
Average Tenure
61yo
Average Age
Experienced Management: 4572's management team is seasoned and experienced (12.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Representative Director | 21.7yrs | no data | 1.75% ¥ 98.5m | |
| GM of Business Mgt. | 8.8yrs | no data | 0.29% ¥ 16.1m | |
| GM of Research & Development Division | 9.8yrs | no data | 0.56% ¥ 31.3m | |
| Head of Drug Discovery & Support Business | 20.8yrs | no data | 0.53% ¥ 30.1m | |
| GM of Clinical Development | 1.8yrs | no data | 0.086% ¥ 4.9m | |
| Independent Outside Director | 4.9yrs | no data | 0.026% ¥ 1.5m | |
| Independent Outside Director | 4.9yrs | no data | 0.042% ¥ 2.4m | |
| Independent Outside Director | 9.8yrs | no data | 0.0058% ¥ 324.5k | |
| Independent Outside Director | 4.9yrs | no data | no data | |
| Independent Outside Director | less than a year | no data | no data |
6.8yrs
Average Tenure
75yo
Average Age
Experienced Board: 4572's board of directors are considered experienced (6.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 03:18 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Carna Biosciences, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yen Ting Chen | Credit Suisse |
| Tsuyoshi Ohno | Marusan Securities Co. Ltd. |